DrugPatentWatch Database Preview
Encorafenib - Generic Drug Details
What are the generic sources for encorafenib and what is the scope of encorafenib freedom to operate?
Encorafenib
is the generic ingredient in one branded drug marketed by Array Biopharma Inc and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.Encorafenib has one hundred and eight patent family members in forty-six countries.
One supplier is listed for this compound.
Summary for encorafenib
| International Patents: | 108 |
| US Patents: | 11 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 32 |
| Clinical Trials: | 8 |
| Patent Applications: | 64 |
| DailyMed Link: | encorafenib at DailyMed |
Synonyms for encorafenib
| 1269440-17-6 |
| 8L7891MRB6 |
| AC-30230 |
| AKOS027254498 |
| AS-35201 |
| BDBM221688 |
| Carbamic acid, N-[(1S)-2-[[4-[3-[5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl]-1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-1-methylethyl]-, methyl ester |
| CHEMBL3301612 |
| CMJCXYNUCSMDBY-ZDUSSCGKSA-N |
| CS-2289 |
| D0TK7R |
| D11053 |
| DB11718 |
| DTXSID00155347 |
| Encorafenib (JAN/USAN/INN) |
| Encorafenib (LGX818) |
| Encorafenib [USAN:INN] |
| EX-A1587 |
| GTPL7908 |
| HY-15605 |
| KB-145917 |
| LGX 818 |
| LGX-818 |
| LGX-818(Encorafenib) |
| LGX818 |
| Methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate |
| methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate |
| MolPort-035-395-871 |
| NVP-LGX818 |
| NVP-LGX818-NXA |
| s7108 |
| SCHEMBL8228295 |
| UNII-8L7891MRB6 |
| US9314464, 9 |
| ZINC68249103 |
US Patents and Regulatory Information for encorafenib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-001 | Jun 27, 2018 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-002 | Jun 27, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-002 | Jun 27, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-001 | Jun 27, 2018 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-001 | Jun 27, 2018 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-001 | Jun 27, 2018 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-002 | Jun 27, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for encorafenib
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 201491007 | ➤ Sign Up |
| Peru | 19942014 | ➤ Sign Up |
| Singapore | 11201401260Q | ➤ Sign Up |
| New Zealand | 623628 | ➤ Sign Up |
| Brazil | 112014011981 | ➤ Sign Up |
| Hungary | E032847 | ➤ Sign Up |
| Canada | 2856406 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
